Antibacterial residue excretion via urine as an indicator for therapeutical treatment choice and farm waste treatment

Serrano Andrés, María Jesús ; García-Gonzalo, Diego (Universidad de Zaragoza) ; Elorduy Goyeneche, Janire ; Mitjana Nerín, Olga (Universidad de Zaragoza) ; Falceto Recio, Mª Victoria (Universidad de Zaragoza) ; Laborda García, Alicia (Universidad de Zaragoza) ; Bonastre Ráfales, Cristina (Universidad de Zaragoza) ; Mata Vallespín, Luis ; Condón Usón, Santiago (Universidad de Zaragoza) ; Pagán Tomás, Rafael. (Universidad de Zaragoza)

Resumen: Many of the infectious diseases that affect livestock have bacteria as etiological agents. Thus, therapy is based on antimicrobials that leave the animal’s tissues mainly via urine, reaching the environment through slurry and waste water. Once there, antimicrobial residues may lead to antibacterial resistance as well as toxicity for plants, animals, or humans. Hence, the objective was to describe the rate of antimicrobial excretion in urine in order to select the most appropriate molecule while reducing harmful effects. Thus, 62 pigs were treated with sulfamethoxypyridazine, oxytetracycline, and enrofloxacin. Urine was collected through the withdrawal period and analysed via LC-MS/MS. Oxytetracycline had the slowest rate of degradation (a half-life time of 4.18 days) and the most extended elimination period in urine (over 2 months), followed by enrofloxacin (a half-life time of 1.48 days, total urine elimination in ca. 3 weeks) and sulfamethoxypyridazine (a half-life time of 0.49 days, total urine elimination in ca. 1 week). Bacterial sensitivity and recommendations for responsible use are limiting when selecting the treatment. Nevertheless, with similar effectiveness, sulfamethoxypyridazine would be the choice, as waste treatment would only need to be implemented for 1 week after treatment. Thus, more in-depth knowledge regarding antibacterial elimination would improve resource management, while protecting animals and consumers’ health.

Idioma: Inglés

DOI: 10.3390/antibiotics10070762

Año: 2021

Publicado en: Antibiotics 10, 7 (2021), 762 [14 pp.]
ISSN: 2079-6382

Factor impacto JCR: 5.222 (2021)

Categ. JCR: PHARMACOLOGY & PHARMACY rank: 68 / 279 = 0.244 (2021) - Q1 - T1
Categ. JCR: INFECTIOUS DISEASES rank: 39 / 96 = 0.406 (2021) - Q2 - T2

Factor impacto CITESCORE: 3.9 - Medicine (Q2) - Pharmacology, Toxicology and Pharmaceutics (Q2) - Immunology and Microbiology (Q3) - Biochemistry, Genetics and Molecular Biology (Q3)

Factor impacto SCIMAGO: 0.785 - Biochemistry (Q1) - Microbiology (Q1) - Pharmacology, Toxicology and Pharmaceutics (miscellaneous) (Q1) - Pharmacology (medical) (Q1) - Microbiology (medical) (Q1)

Financiación: info:eu-repo/grantAgreement/EUR/INTERREG-V-A-POCTEFA-2014-2020

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Medicina y Cirugía Animal (Dpto. Patología Animal)
Área (Departamento): Área Tecnología de Alimentos (Dpto. Produc.Animal Cienc.Ali.)